Baidu
map

专题:危重症患者诊疗指南干货,速速围观!

2017-05-27 MedSci MedSci原创

现代诊疗技术的快速发展,高精尖的医疗设备得到了广泛的应用,对从事危重症患者诊疗的医务人员素质提出了更高的要求,危重症的专业性和综合性都比较强,它整合了内科、外科、护理等多个专业的高端技术。危重病人的病情严重随时可能变化,如果抢救及时,护理得当,病人可能转危为安,反之,即可发生生命危险。因此对危重病人的护理是一项非常重要而严肃的工作,是争分夺秒的战斗。梅斯小编整理了危重症患者诊疗相关指南,供大家参考


现代诊疗技术的快速发展,高精尖的医疗设备得到了广泛的应用,对从事危重症患者诊疗的医务人员素质提出了更高的要求,危重症的专业性和综合性都比较强,它整合了内科、外科、护理等多个专业的高端技术。危重病人的病情严重随时可能变化,如果抢救及时,护理得当,病人可能转危为安,反之,即可发生生命危险。因此对危重病人的护理是一项非常重要而严肃的工作,是争分夺秒的战斗。梅斯小编整理了危重症患者诊疗相关指南,供大家参考! 
一、规范篇 
1、中国卫生行业标准-重症监护病房医院感染预防与控制规范(WS/T509-2016) 
本标准规定了医疗机构重症监护病房(ICU)医院感染预防与控制的基本要求、建筑布局与必要设施及管理要求、人员管理、医院感染的监测、器械相关感染的预防和控制措施、手术部位感染的预防与控制措施、手卫生要求、环境清洁消毒方法与要求、床单元的清洁与消毒要求、便器的清洗与消毒要求、空气消毒方法与要求等。本标准适用各级综合医院依据有关规定设置的ICU。 2、急诊危重症患者院内转运共识——标准化分级转运方案 
鉴于急危重症患者具有病情危重、病情变化快、且常常依赖生命支持手段及转运难度大等特点,因此亟需规范并优化院内转运流程,以保证急危重症患者院内转运安全。根据急诊危重症患者的特点以及急诊院内转运的临床实践,本共识协作组制定了“降阶梯预案、充分评估、优化分级、最佳路径、动态评估”为原则的分级转运方案,以保证转运安全。 二、诊疗篇
1、2016 ATS/ACCP临床实践指南:危重症患者机械通气撤机 
2016年10月,美国胸科学会(ATS)、美国胸科医师学会(ACCP)发布了危重症患者机械通气撤机指南,指南专家组共提出了与康复协议,呼吸机撤机协议,以及气囊漏气试验相关的4条建议。 2、床旁超声在急危重症临床应用的专家共识 
随着超声技术的发展和普 及,特别是肺部超声的突破,床旁超声为急诊医师提供了越来越多急危重症患者的临床信息,被誉为可视 “听诊器”, 因此,急诊床旁超声也受到急诊医师的广泛关注。本共识以 急诊临床思维为导向,结合国内外超声发展现状,主要针对几种常见的急危症超声影像和流程进行梳理,进一步规范和 推广急诊床旁超声的临床应用。 3、支气管镜在急危重症临床应用的专家共识 
按照卫计委《呼吸内镜诊疗技术管理规范2012》规定:有3年以上临床工作经验,累计参与呼吸内镜诊疗技术操作50例次者即可独立进行操作。因此,每个进行气管镜操作的急诊医生都应该在经验丰富的上级医师指导下,接受系统正规的气管镜的理论与实践紧密结合的培训,最终能够独立、规范地处理临床常见问题。 4、谷氨酰胺在危重症患者中临床应用的专家推荐意见(节录) 
谷氨酰胺(glutamine,GLN)作为人体氨基酸之一,广泛地参与机体的各种生物活动。研究表明,在危重症状况下,适宜的GLN 供给对于维持正常肠屏障功能、降低炎性介质水平是必需的[1]。但最近也有一些重要的质疑性研究,对GLN 的临床应用引起不同意见的争论。

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (7)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1707443, encodeId=a8eb1e0744397, content=<a href='/topic/show?id=25df20e54dc' target=_blank style='color:#2F92EE;'>#专题#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20754, encryptionId=25df20e54dc, topicName=专题)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f4231418733, createdName=108807375_62823137, createdTime=Tue Aug 22 04:54:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284000, encodeId=fe621284000f6, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Mon May 29 01:54:00 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526127, encodeId=a764152612ef5, content=<a href='/topic/show?id=a08b36e6548' target=_blank style='color:#2F92EE;'>#危重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36765, encryptionId=a08b36e6548, topicName=危重症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfbf11697948, createdName=liuquan, createdTime=Mon May 29 01:54:00 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203365, encodeId=9242203365e7, content=学习了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sun May 28 00:06:42 CST 2017, time=2017-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203224, encodeId=ebbd20322403, content=比较全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwF3IOBZ2PuqN4kVibCFp38BFYZ90a6ib4FiaNtfuyfaVl9kdqIuS7cYIicicMdkX3KteMgTwK54c4ybH/0, createdBy=f2571354424, createdName=wangxy0513, createdTime=Sat May 27 13:55:13 CST 2017, time=2017-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203212, encodeId=fcf820321200, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K6uiaa8Rp49ibOhXXPica7icVOgRWzYu3UJYe0BpHicBXialCN3bbvN85QtImfQVRMgCQkfGbL4c0bv1jD/0, createdBy=f7c21673796, createdName=guangyi1980, createdTime=Sat May 27 12:42:13 CST 2017, time=2017-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203207, encodeId=0b4920320e19, content=学习了!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Sat May 27 11:57:35 CST 2017, time=2017-05-27, status=1, ipAttribution=)]
  2. [GetPortalCommentsPageByObjectIdResponse(id=1707443, encodeId=a8eb1e0744397, content=<a href='/topic/show?id=25df20e54dc' target=_blank style='color:#2F92EE;'>#专题#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20754, encryptionId=25df20e54dc, topicName=专题)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f4231418733, createdName=108807375_62823137, createdTime=Tue Aug 22 04:54:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284000, encodeId=fe621284000f6, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Mon May 29 01:54:00 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526127, encodeId=a764152612ef5, content=<a href='/topic/show?id=a08b36e6548' target=_blank style='color:#2F92EE;'>#危重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36765, encryptionId=a08b36e6548, topicName=危重症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfbf11697948, createdName=liuquan, createdTime=Mon May 29 01:54:00 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203365, encodeId=9242203365e7, content=学习了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sun May 28 00:06:42 CST 2017, time=2017-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203224, encodeId=ebbd20322403, content=比较全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwF3IOBZ2PuqN4kVibCFp38BFYZ90a6ib4FiaNtfuyfaVl9kdqIuS7cYIicicMdkX3KteMgTwK54c4ybH/0, createdBy=f2571354424, createdName=wangxy0513, createdTime=Sat May 27 13:55:13 CST 2017, time=2017-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203212, encodeId=fcf820321200, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K6uiaa8Rp49ibOhXXPica7icVOgRWzYu3UJYe0BpHicBXialCN3bbvN85QtImfQVRMgCQkfGbL4c0bv1jD/0, createdBy=f7c21673796, createdName=guangyi1980, createdTime=Sat May 27 12:42:13 CST 2017, time=2017-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203207, encodeId=0b4920320e19, content=学习了!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Sat May 27 11:57:35 CST 2017, time=2017-05-27, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1707443, encodeId=a8eb1e0744397, content=<a href='/topic/show?id=25df20e54dc' target=_blank style='color:#2F92EE;'>#专题#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20754, encryptionId=25df20e54dc, topicName=专题)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f4231418733, createdName=108807375_62823137, createdTime=Tue Aug 22 04:54:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284000, encodeId=fe621284000f6, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Mon May 29 01:54:00 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526127, encodeId=a764152612ef5, content=<a href='/topic/show?id=a08b36e6548' target=_blank style='color:#2F92EE;'>#危重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36765, encryptionId=a08b36e6548, topicName=危重症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfbf11697948, createdName=liuquan, createdTime=Mon May 29 01:54:00 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203365, encodeId=9242203365e7, content=学习了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sun May 28 00:06:42 CST 2017, time=2017-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203224, encodeId=ebbd20322403, content=比较全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwF3IOBZ2PuqN4kVibCFp38BFYZ90a6ib4FiaNtfuyfaVl9kdqIuS7cYIicicMdkX3KteMgTwK54c4ybH/0, createdBy=f2571354424, createdName=wangxy0513, createdTime=Sat May 27 13:55:13 CST 2017, time=2017-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203212, encodeId=fcf820321200, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K6uiaa8Rp49ibOhXXPica7icVOgRWzYu3UJYe0BpHicBXialCN3bbvN85QtImfQVRMgCQkfGbL4c0bv1jD/0, createdBy=f7c21673796, createdName=guangyi1980, createdTime=Sat May 27 12:42:13 CST 2017, time=2017-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203207, encodeId=0b4920320e19, content=学习了!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Sat May 27 11:57:35 CST 2017, time=2017-05-27, status=1, ipAttribution=)]
  4. [GetPortalCommentsPageByObjectIdResponse(id=1707443, encodeId=a8eb1e0744397, content=<a href='/topic/show?id=25df20e54dc' target=_blank style='color:#2F92EE;'>#专题#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20754, encryptionId=25df20e54dc, topicName=专题)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f4231418733, createdName=108807375_62823137, createdTime=Tue Aug 22 04:54:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284000, encodeId=fe621284000f6, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Mon May 29 01:54:00 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526127, encodeId=a764152612ef5, content=<a href='/topic/show?id=a08b36e6548' target=_blank style='color:#2F92EE;'>#危重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36765, encryptionId=a08b36e6548, topicName=危重症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfbf11697948, createdName=liuquan, createdTime=Mon May 29 01:54:00 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203365, encodeId=9242203365e7, content=学习了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sun May 28 00:06:42 CST 2017, time=2017-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203224, encodeId=ebbd20322403, content=比较全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwF3IOBZ2PuqN4kVibCFp38BFYZ90a6ib4FiaNtfuyfaVl9kdqIuS7cYIicicMdkX3KteMgTwK54c4ybH/0, createdBy=f2571354424, createdName=wangxy0513, createdTime=Sat May 27 13:55:13 CST 2017, time=2017-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203212, encodeId=fcf820321200, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K6uiaa8Rp49ibOhXXPica7icVOgRWzYu3UJYe0BpHicBXialCN3bbvN85QtImfQVRMgCQkfGbL4c0bv1jD/0, createdBy=f7c21673796, createdName=guangyi1980, createdTime=Sat May 27 12:42:13 CST 2017, time=2017-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203207, encodeId=0b4920320e19, content=学习了!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Sat May 27 11:57:35 CST 2017, time=2017-05-27, status=1, ipAttribution=)]
    2017-05-28 明天会更好!

    学习了,谢谢分享!

    0

  5. [GetPortalCommentsPageByObjectIdResponse(id=1707443, encodeId=a8eb1e0744397, content=<a href='/topic/show?id=25df20e54dc' target=_blank style='color:#2F92EE;'>#专题#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20754, encryptionId=25df20e54dc, topicName=专题)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f4231418733, createdName=108807375_62823137, createdTime=Tue Aug 22 04:54:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284000, encodeId=fe621284000f6, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Mon May 29 01:54:00 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526127, encodeId=a764152612ef5, content=<a href='/topic/show?id=a08b36e6548' target=_blank style='color:#2F92EE;'>#危重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36765, encryptionId=a08b36e6548, topicName=危重症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfbf11697948, createdName=liuquan, createdTime=Mon May 29 01:54:00 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203365, encodeId=9242203365e7, content=学习了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sun May 28 00:06:42 CST 2017, time=2017-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203224, encodeId=ebbd20322403, content=比较全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwF3IOBZ2PuqN4kVibCFp38BFYZ90a6ib4FiaNtfuyfaVl9kdqIuS7cYIicicMdkX3KteMgTwK54c4ybH/0, createdBy=f2571354424, createdName=wangxy0513, createdTime=Sat May 27 13:55:13 CST 2017, time=2017-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203212, encodeId=fcf820321200, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K6uiaa8Rp49ibOhXXPica7icVOgRWzYu3UJYe0BpHicBXialCN3bbvN85QtImfQVRMgCQkfGbL4c0bv1jD/0, createdBy=f7c21673796, createdName=guangyi1980, createdTime=Sat May 27 12:42:13 CST 2017, time=2017-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203207, encodeId=0b4920320e19, content=学习了!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Sat May 27 11:57:35 CST 2017, time=2017-05-27, status=1, ipAttribution=)]
    2017-05-27 wangxy0513

    比较全面

    0

  6. [GetPortalCommentsPageByObjectIdResponse(id=1707443, encodeId=a8eb1e0744397, content=<a href='/topic/show?id=25df20e54dc' target=_blank style='color:#2F92EE;'>#专题#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20754, encryptionId=25df20e54dc, topicName=专题)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f4231418733, createdName=108807375_62823137, createdTime=Tue Aug 22 04:54:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284000, encodeId=fe621284000f6, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Mon May 29 01:54:00 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526127, encodeId=a764152612ef5, content=<a href='/topic/show?id=a08b36e6548' target=_blank style='color:#2F92EE;'>#危重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36765, encryptionId=a08b36e6548, topicName=危重症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfbf11697948, createdName=liuquan, createdTime=Mon May 29 01:54:00 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203365, encodeId=9242203365e7, content=学习了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sun May 28 00:06:42 CST 2017, time=2017-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203224, encodeId=ebbd20322403, content=比较全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwF3IOBZ2PuqN4kVibCFp38BFYZ90a6ib4FiaNtfuyfaVl9kdqIuS7cYIicicMdkX3KteMgTwK54c4ybH/0, createdBy=f2571354424, createdName=wangxy0513, createdTime=Sat May 27 13:55:13 CST 2017, time=2017-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203212, encodeId=fcf820321200, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K6uiaa8Rp49ibOhXXPica7icVOgRWzYu3UJYe0BpHicBXialCN3bbvN85QtImfQVRMgCQkfGbL4c0bv1jD/0, createdBy=f7c21673796, createdName=guangyi1980, createdTime=Sat May 27 12:42:13 CST 2017, time=2017-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203207, encodeId=0b4920320e19, content=学习了!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Sat May 27 11:57:35 CST 2017, time=2017-05-27, status=1, ipAttribution=)]
    2017-05-27 guangyi1980

    学习了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1707443, encodeId=a8eb1e0744397, content=<a href='/topic/show?id=25df20e54dc' target=_blank style='color:#2F92EE;'>#专题#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=50, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=20754, encryptionId=25df20e54dc, topicName=专题)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=1f4231418733, createdName=108807375_62823137, createdTime=Tue Aug 22 04:54:00 CST 2017, time=2017-08-22, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1284000, encodeId=fe621284000f6, content=<a href='/topic/show?id=cdb79594643' target=_blank style='color:#2F92EE;'>#重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=70, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95946, encryptionId=cdb79594643, topicName=重症患者)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=6c3a189, createdName=longqijun248, createdTime=Mon May 29 01:54:00 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1526127, encodeId=a764152612ef5, content=<a href='/topic/show?id=a08b36e6548' target=_blank style='color:#2F92EE;'>#危重症患者#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=64, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=36765, encryptionId=a08b36e6548, topicName=危重症患者)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=bfbf11697948, createdName=liuquan, createdTime=Mon May 29 01:54:00 CST 2017, time=2017-05-29, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203365, encodeId=9242203365e7, content=学习了,谢谢分享!, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://cacheapi.medsci.cn/resource/upload/20160914/IMG57D82E721DB581755.jpg, createdBy=4fc81933929, createdName=明天会更好!, createdTime=Sun May 28 00:06:42 CST 2017, time=2017-05-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203224, encodeId=ebbd20322403, content=比较全面, beContent=null, objectType=article, channel=null, level=null, likeNumber=100, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5KwF3IOBZ2PuqN4kVibCFp38BFYZ90a6ib4FiaNtfuyfaVl9kdqIuS7cYIicicMdkX3KteMgTwK54c4ybH/0, createdBy=f2571354424, createdName=wangxy0513, createdTime=Sat May 27 13:55:13 CST 2017, time=2017-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203212, encodeId=fcf820321200, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=76, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/oLAjfB7s1ib06iaV3D9Tg5K6uiaa8Rp49ibOhXXPica7icVOgRWzYu3UJYe0BpHicBXialCN3bbvN85QtImfQVRMgCQkfGbL4c0bv1jD/0, createdBy=f7c21673796, createdName=guangyi1980, createdTime=Sat May 27 12:42:13 CST 2017, time=2017-05-27, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=203207, encodeId=0b4920320e19, content=学习了!!!!!, beContent=null, objectType=article, channel=null, level=null, likeNumber=74, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=078f1661649, createdName=wei834766788, createdTime=Sat May 27 11:57:35 CST 2017, time=2017-05-27, status=1, ipAttribution=)]
    2017-05-27 wei834766788

    学习了!!!!!

    0

相关资讯

危重症的早期信号及临床特点

随着基层卫生事业的快速发展,基层急救越来越受到关注,基层急救的关键环节是基层医生对危重症的早期识别和及时的处置干预。 急危重症是紧急、濒危的病症,其来势凶、变化快,早期判断与快速处置直接影响到患者的生命安危,因此,全科医师需要练就“火眼金睛”,快速识别急危重症并进行初步处理,与院前急救配合做到安全转运,提高危重病人的抢救成功率。 基层常见急危重症症状包括胸闷、胸痛、呼吸困难、昏

危重症的早期信号及临床特点

随着基层卫生事业的快速发展,基层急救越来越受到关注,基层急救的关键环节是基层医生对危重症的早期识别和及时的处置干预。急危重症是紧急、濒危的病症,其来势凶、变化快,早期判断与快速处置直接影响到患者的生命安危,因此,全科医师需要练就“火眼金睛”,快速识别急危重症并进行初步处理,与院前急救配合做到安全转运,提高危重病人的抢救成功率。基层常见急危重症症状包括胸闷、胸痛、呼吸困难、昏迷、抽搐及休克等;猝死的

青年医生朱元方:以生命名义与时间赛跑

时间就是生命。这句话对他来说意义非常。“每一个危重症孕妇的抢救都是一场与时间的赛跑,只有争分夺秒才能赢过死神,挽救新生命,挽救家庭。”作为一名青年妇产科医生,他争分夺秒工作,不放弃任何一位危重症孕产妇的健康;争分夺秒学习,勇攀医学高峰,创造了江西省危重症孕产妇救治的多个第一。在平凡的岗位上,他用自己的实际行动诠释了一个共产党员的优秀品质。他,就是南昌大学一附院妇产科副主任、产科主任、年轻的医学专家

AJRCCM:他汀类可降低危重症患者发生谵妄的风险

这是一项前瞻性队列研究,来自英国的研究者们考察了他汀类药物治疗是否有助降低危重症患者出现谵妄的风险,其研究结果在线发表在2014年3月15日的《美国呼吸和危重治疗医学杂志》(American Journal of Respiratory and Critical Care Medicine)危重监护病房(ICU)内的患者常出现谵妄,并且与不良转归有关。神经炎症可能是潜在的发病机制。由于他汀类具有抗

Baidu
map
Baidu
map
Baidu
map